Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Glioblastoma, IDH-Wildtype

OncoTree code GB · 5 articles

Clinical · Molecular biology · Bioinfo & AI

Complementary use of the DNA methylation-based tumor classification by the Bethesda v3 classifier in routine diagnostics: evaluation in a series of 516 cases

Brandenburg C, Starzetz T, Woltering N, et al.

Acta neuropathologica

This study evaluates the performance of the DNA methylation-based Bethesda Classifier v3 (Bv3) for central nervous system (CNS) tumor diagnosis. Bv3 was tested on 516 samples, including straightforward cases and diagnostically challenging cases previously unclassifiable by the Heidelberg Classifier v12.8. It achieved correct classification in 97% of straightforward cases and successfully classified 56% of complex cases, with a low misclassification rate of 4%. The findings suggest that Bv3 is a robust complementary tool for routine neuropathological diagnostics, even for samples with low DNA concentration.

Clinical · Molecular biology · Bioinfo & AI

Segmental Copy Number Variant Detection Using an Amplicon-Based Next-Generation Sequencing Panel for Integrated Glioma Classification

Sarvananthan K, Santos S, Saylor B, et al.

The Journal of molecular diagnostics

This study describes a custom analysis method for detecting segmental copy number variants (CNVs) using an amplicon-based NGS panel (Oncomine Comprehensive Assay v3) for integrated glioma classification. The developed algorithm identifies critical biomarkers such as 1p/19q codeletion, +7/-10, EGFR amplification, and CDKN2A/B homozygous deletion. Validated across three cohorts, the approach demonstrated 100% concordance with FISH for all biomarkers in the validation cohort. Its clinical implementation significantly reduced required FISH studies by 90%, thereby shortening turnaround times and decreasing molecular testing costs.

Clinical · Molecular biology

Independent associations of MGMT promoter methylation and TERT promoter mutation with overall survival in glioblastoma: a single-center retrospective cohort study

Cengiz A, Yıldızhan S, Rakip U, et al.

Neurological sciences

This single-center retrospective study investigated the prognostic impact of MGMT promoter methylation and TERT promoter mutations in 54 patients with WHO grade 4 glioblastoma. The findings indicate that MGMT methylation is independently associated with improved overall survival, whereas TERT mutations predict worse survival. Adjuvant chemoradiotherapy was also confirmed to improve outcomes. A combined stratification using both biomarkers allows for the identification of four distinct prognostic subgroups, with MGMT-methylated/TERT-wild-type patients exhibiting the longest survival.

Clinical · Molecular biology

Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma

Park J, Qiu M, Cho EJ, et al.

Cell reports. Medicine

This study established 18 patient-derived glioblastoma organoid (GBO) lines that faithfully preserve the histopathological and genomic features of parental tumors. Glioblastoma organoid-based drug sensitivity testing (GBO-DST) demonstrated a strong correlation with progression-free survival and proved superior to MGMT methylation status in predicting temozolomide response. Transcriptomic analysis elucidated mechanisms of temozolomide resistance, including mismatch repair deficiency and elevated MGMT expression. Furthermore, FDA-approved drug screening using GBO-DST identified regorafenib and lazertinib as effective therapeutic alternatives, with lazertinib showing superior efficacy in a GBO transplantation mouse model. These findings highlight the significant potential of GBO-DST as a robust platform for precision oncology in glioblastoma.

Clinical · Molecular biology

Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations

Seifert AM, Richter S, Sagerer A, et al.

Journal of neuro-oncology

This study compared clinical characteristics and survival between molecularly defined IDH-wild-type glioblastoma (MolGBM) and histologically defined IDH-wild-type glioblastoma (HistGBM). It also characterized lower-grade IDH-wild-type astrocytic tumors lacking glioblastoma-defining genomic alterations. MolGBM exhibited a more favorable adjusted overall survival (HR 0.40) compared to HistGBM, particularly in patients aged 60 years or older. These findings highlight the clinical and biological heterogeneity among molecularly defined IDH-wild-type diffuse gliomas and the critical role of comprehensive molecular characterization. Lower-grade IDH-wild-type astrocytic tumors without glioblastoma-defining alterations warrant further in-depth molecular investigation.